Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

NCT05958342 · View on ClinicalTrials.gov ↗

Study Summary

The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.

Conditions Studied

Interventions

  • DRUG Calcium Gluconate
  • DRUG Vasopressin
  • DRUG saline placebo

Study Locations (13)

Pennsylvania

  • Allegheny Health Network — Pittsburgh
  • University of Pittsburgh — Pittsburgh

Arizona

  • University of Arizona — Tucson

Arkansas

  • University of Arkansas for Medical Sciences — Little Rock

California

  • Zuckerberg San Francisco General Hospital and Trauma Center at University of California, San Francisco — San Francisco

Colorado

  • Denver Health Medical Center — Denver

Florida

  • University of Miami — Miami

Minnesota

  • Hennepin County Medical Center — Minneapolis

Missouri

  • University of Missouri Health Care — Columbia

Trial Details

FieldValue
Enrollment Target 1,050 participants
Start Date 2024-06-30
Est. Completion 2028-03
Phase Phase 2

Sponsor

Jason Sperry

33 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05958342

The ClinicalTrials.gov registry entry for NCT05958342 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Sperry, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Trauma appearing as the primary indexed condition, and to 3 interventions — of which Calcium Gluconate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05958342 reports 13 study locations spanning 12 distinct geographic areas — top geographies include Pennsylvania, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05958342 about?

NCT05958342 is a clinical study titled "CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial". The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patie...

What is the current status of trial NCT05958342?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,050 participants. The study started on 2024-06-30. Estimated completion is 2028-03.

What conditions does trial NCT05958342 study?

This clinical trial studies the following conditions: Trauma, Hemorrhage. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05958342?

The interventions under investigation include: Calcium Gluconate (DRUG), Vasopressin (DRUG), saline placebo (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05958342?

This trial is sponsored by Jason Sperry, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05958342 being conducted?

This trial has 13 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial